FAS and breast carcinoma: Another FAS inhibitor, BI99179, showed preclinical efficacy by diminishing lipid synthesis and palmitate levels in vitro and by reducing brain tumor growth in mouse xenografts generated by the intracranial implantation of a breast cancer cell line [30].